BCL2L11 and Burkitt lymphoma: EBNA3A and EBNA3C have been shown to silence BCL2L11 with concomitant recruitment of PRC2, leading to an increased level of H3K27me3 while DNA methylation at the BCL2L11 promoter CpG island was found in EBV-positive BL cells (25, 47, 48).